Format

Send to

Choose Destination
Science. 2016 May 20;352(6288):997-1001. doi: 10.1126/science.aaf0972. Epub 2016 May 5.

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Author information

1
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
2
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA. Laboratory of Experimental Immunology, Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany. Department of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, 50937 Cologne, Germany.
3
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA. Albert Ludwigs University of Freiburg, Freiburg, Germany.
4
Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
5
Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Campus E14, 66123 Saarbrücken, Germany.
6
Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
7
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
8
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
9
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA. Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.

Abstract

3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02018510.

PMID:
27199429
PMCID:
PMC5151174
DOI:
10.1126/science.aaf0972
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center